Daily pill doubles survival time for pancreatic cancer patients in groundbreaking trial
A new daily pill has shown it can double survival time for patients with pancreatic cancer, one of the deadliest forms of the disease. The clinical trial results have been hailed as a major breakthrough by experts. The podcast explores how the drug, daraxonrasib, works and its potential impact on patient care.
Source: Guardian Science
Read the full story